Recent Company News

• 07:11 AM ET Oct 18, 2025
  

  Celcuity presents updated data from Phase 1 trial evaluating gedatolisib in combination with Nubeqa in men with mCRPC ($51.96, 0.00)

• 05:11 AM ET Oct 06, 2025
  

  Celltrion presents positive real-world data on the use of subcutaneous infliximab at MTE Sessions at UEG 2025 (KRW 175400.0000, 0)

• 04:00 AM ET Sep 26, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 02:35 AM ET Oct 06, 2025
  

  Orion upgraded to buy from hold at Nordea (€65.30, 0.00)

• 06:07 AM ET Sep 30, 2025
  

  Orion's phase 2 study of ODM-105 in insomnia did not meet primary goal (€63.75, -0.70)

• 12:50 PM ET Sep 26, 2025
  

  White House says the latest pharmaceutical tariffs do not apply to countries with negotiated trade deals -- wires

• 02:53 AM ET Sep 26, 2025
  

  StreetAccount Summary - European pre-market trading update

• 08:15 PM ET Sep 25, 2025
  

  Trump says pharmaceutical products imported into US will be hit with 100% tariff starting 1-Oct - Truth Social post

• 09:01 AM ET Aug 21, 2025
  

  Health Canada grants marketing authorization for an additional indication of Bayer's NUBEQA (darolutamide) for the treatment of metastatic castration-sensitive prostate cancer (mCSPC) (€27.92, -0.03)